Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Meditation and Yogic Breathing-driven Modulation of Neurofluid Coupling and Brain Clearance (SPANDHA)

5 de novembro de 2026 atualizado por: Balachundhar Subramaniam, Beth Israel Deaconess Medical Center

This study will examine whether meditation and yogic breathing can alter brain fluid movement and waste clearance in healthy adults. It will also evaluate the GLYMPHOMETER, a new external forehead-worn device designed to objectively measure changes in brain fluid movement and exchange during meditation.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Descrição detalhada

The glymphatic system is a brain waste-clearance pathway that facilitates the movement of cerebrospinal fluid (CSF) and interstitial fluid and is thought to play an important role in maintaining brain homeostasis. Emerging evidence suggests that respiration, autonomic activity, and changes in cerebral blood flow may influence CSF dynamics and related neurofluid processes. However, the effects of voluntary breathing practices and meditation on these physiological mechanisms in humans remain incompletely understood.

The SPANDHA study will investigate whether structured yogic breathing (Pranayama; specifically Nadi Shuddhi) and/or meditation (Shoonya meditation) are associated with changes in neurofluid dynamics and related physiological measures. The study will use the GLYMPHOMETER, a forehead-mounted multimodal device designed to measure physiological signals associated with neurofluid coupling during naturalistic meditation and breathing practices. The system incorporates multi-wavelength electroencephalography (EEG) and near-infrared spectroscopy (NIRS) to characterize changes in cerebral electrical activity, cerebral hemodynamics, and neurofluid-related dynamics while participants engage in the interventions.

The study will enroll approximately 100 participants, including 50 novice and 50 experienced practitioners. Using a 2-sequence crossover, participants will complete two study visits involving meditation and yogic breathing conditions. The study will evaluate changes in measures of neurofluid dynamics, cerebral compliance, autonomic regulation including heart-rate variability (HRV), and EEG-derived brain states associated with the interventions. Participants will be stratified by experience level (novice/advance) and randomized within each stratum to one of the two intervention sequences.

A subset of participants will undergo additional validation assessments using phase-contrast magnetic resonance imaging (MRI) and blood-based biomarkers. These assessments will be used to examine the relationship between measurements obtained with the GLYMPHOMETER and established measures of CSF and cerebrovascular physiology.

The primary objective of the study is to characterize the acute physiological effects of meditation and yogic breathing on neurofluid dynamics and related brain and autonomic measures. The findings may provide preliminary evidence regarding the feasibility of using voluntary breathing and meditation practices to modulate physiological processes associated with glymphatic function and may inform future studies of non-pharmacological approaches to brain health.

Tipo de estudo

Intervencional

Inscrição (Estimado)

120

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

25 anos a 60 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Healthy adults, 25-60 years old.
  • Novice or Advanced as defined above.
  • Fluent in English.
  • Able to travel to BIDMC site for two days approximately 3-7 days apart.

Exclusion Criteria:

  • History of neurological and/or neurodegenerative disorders (e.g., epilepsy, stroke, mild cognitive impairment, dementia)
  • History of cardiovascular and respiratory illnesses
  • History of major psychiatric disorders (e.g., schizophrenia, bipolar disorder)
  • Currently diagnosed mental health issues (e.g., anxiety, depression)
  • Current use of psychoactive medications, including medications prescribed for anxiety, depression, or other psychiatric conditions, or current use of stimulants or other medications that may substantially affect central nervous system function or study outcomes.
  • Skin ailments, abrasions or contusions, particularly located on the forehead and face

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Novice Meditators

Less than 1 year of consistent meditation practice.

Nadi Shuddhi is a structured yogic breathing practice involving slow, alternating respiration through the left and right nostrils in a prescribed sequence.

Shoonya meditation is a structured contemplative practice characterized by conscious non-doing, in which participants maintain a relaxed, alert state while minimizing deliberate attentional selection, cognitive elaboration, and engagement with internal or external stimuli.

Comparador Ativo: Advanced Meditators

More than 5 years or a minimum of 2500 hours of consistent meditation practice

Nadi Shuddhi is a structured yogic breathing practice involving slow, alternating respiration through the left and right nostrils in a prescribed sequence.

Shoonya meditation is a structured contemplative practice characterized by conscious non-doing, in which participants maintain a relaxed, alert state while minimizing deliberate attentional selection, cognitive elaboration, and engagement with internal or external stimuli.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Acquisition of physiological data using the GLYMPHOMETER during meditation and yogic breathing sessions.
Prazo: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Participants meeting threshold for analyzable device recordings.

At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Neurofluid-related physiological measures during Shoonya meditation and Nadi Shuddhi breathing.
Prazo: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Changes in GLYMPHOMETER-derived measures of neurofluid coupling, during Shoonya meditation and Nadi Shuddhi breathing.

(Measurement device: Glymphometer; Measure: Neurofluid coupling aka Fluid dynamics in brain)

At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
Autonomic regulation during Shoonya meditation and Nadi Shuddhi breathing.
Prazo: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Changes in heart-rate variability (HRV) during Shoonya meditation and Nadi Shuddhi breathing.

At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
Very-low-frequency physiological signal characteristics
Prazo: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Changes in predefined very-low-frequency (0.001-0.1 Hz) signal characteristics derived from GLYMPHOMETER medical™ recordings and their relationship to neurofluid-related measures.

At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Differences in neurophysiological responses according to meditation experience.
Prazo: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.

Comparison of changes in GLYMPHOMETER-derived measures of neurofluid coupling between novice and advanced meditators.

From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
Mindful Attention Awareness Scale
Prazo: Once at Baseline. Estimated acquisition window: 5-8 minutes

We assess for change in Mindfulness levels by using a validated scale for this purpose namely, Mindfulness Attention Awareness Scale (MAAS). The scale measures the individuals' ability for receptive awareness and attention to present. This aids in evaluating any change on the individual's awareness levels after the Inner engineering intervention. We compute the MAAS scores for each participant which is a mean score for 15 item questionnaires and compare the pre & post intervention results to look for change. Participants are asked to rate on a scale of 1 (Almost Always) to 6 (Almost Never) to assess the frequency of occurrence of each experience. Mean is then computed using items from each of the 15 questions to create a MAAS score, ranging from 0 to 6. Higher MAAS scores indicate better mindfulness state.

Once at Baseline. Estimated acquisition window: 5-8 minutes
Meditation Depth Questionnaires
Prazo: At each study visit after the meditation practice is completed. Expected acquisition window: 10-15 minutes; Total number of visits: 2

This 30-item measure assesses the subjective depth of meditation across progressively deeper experiential states. Items are typically rated on a 5-point Likert scale and are grouped into five empirically derived domains: hindrances, relaxation, personal-self/concentration, essential/transpersonal qualities, and transpersonal-self/non-duality. Together, these domains capture experiences ranging from obstacles and relaxation during meditation to focused concentration, transpersonal qualities, and experiences of diminished self-boundaries or non-dual awareness.

At each study visit after the meditation practice is completed. Expected acquisition window: 10-15 minutes; Total number of visits: 2
Correlation between GLYMPHOMETER-derived neurofluid metrics and MRI-based neurofluid dynamics (Validation of Portable Device).
Prazo: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.

This outcome evaluates the concurrent validity of the portable device against the gold standard. The statistical method will be a correlation analysis (Pearson or Spearman, as appropriate based on data distribution).

  • Measurement 1 (Variable A): Neurofluid coupling oscillations measured via the GLYMPHOMETER medical™ device (measured as relative changes in HbO, HbR, HbT, and CSF/H2O proportional signal including interhemispheric correlation coefficient across these neurofluid compartments while gating each of them to very low frequency, respiratory and cardiac frequency bands).
  • Measurement 2 (Variable B): Global neurofluid dynamics and CSF flow measured via 3T MRI using fast fMRI and phase-contrast sequences (measured as BOLD-CSF coupling magnitude and CSF stroke volume in mL).
  • Assessment: The study will assess the correlation between the magnitude of oscillatory coupling in Measurement 1 with the absolute flow dynamics in Measurement 2 during the designated validation windows.
From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
Correlation between GLYMPHOMETER-derived neurofluid metrics and plasma brain-derived biomarkers.
Prazo: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.

This outcome evaluates the relationship between neurofluid dynamics and blood-based markers of brain clearance. The statistical method will be a correlation analysis (Pearson or Spearman).

  • Measurement 1 (Variable A): Neurofluid coupling oscillations measured via the GLYMPHOMETER medical™ device (measured as relative changes in HbO, HbR, HbT, and CSF/H2O proportional signal including interhemispheric correlation coefficient across these neurofluidic compartments while gating each of them to very low frequency, respiratory and cardiac frequency bands).
  • Measurement 2 (Variable B): Plasma concentrations of brain-derived proteins/peptides (Aβ40, Aβ42, total/phosphorylated tau, NF-L, GFAP) measured via ultra-sensitive Simoa immunoassay (measured in pg/mL).
  • Assessment: The study will assess the correlation between acute GLYMPHOMETER-derived neurofluid changes and plasma biomarker concentrations before and after intervention.
From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
Qualitative assessment of meditation and breathing experiences.
Prazo: At each study visit after the meditation practice is completed. Expected acquisition window: 30 minutes; Total number of visits: 2

Qualitative characterization of participant experiences using one-on-one micro-phenomenological interviews.

At each study visit after the meditation practice is completed. Expected acquisition window: 30 minutes; Total number of visits: 2

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

16 de novembro de 2026

Conclusão Primária (Estimado)

30 de novembro de 2027

Conclusão do estudo (Estimado)

30 de abril de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

15 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de outubro de 2026

Primeira postagem (Real)

29 de outubro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de novembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 2026P000655
  • GRT69415 (Número de outro subsídio/financiamento: Inner Science Research Foundation)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever